OCI-AML-2Homo sapiens (Human)Cancer cell line

Also known as: Ontario Cancer Institute-Acute Myeloid Leukemia-2, AML-2, OCIAML2, OCI AML2, OCI/AML2, OCI-AML2, OCIAML-2, OCI/AML-2

🤖 AI SummaryBased on 9 publications

OCI-AML2

Quick Overview

Human AML cell line with JAK2 V617F mutation for cancer research.

Detailed Summary

The OCI-AML2 cell line is a human acute myeloid leukemia (AML) cell line derived from a patient with a history of myeloproliferative disorders (MPD) or myelodysplastic syndrome (MDS). It is characterized by the presence of the JAK2 V617F mutation, which is a key driver in myeloproliferative disorders. This cell line is used in research to study the molecular mechanisms of JAK2 mutations and their role in leukemogenesis. The OCI-AML2 cell line has been utilized in studies investigating the effects of JAK2 inhibition and the genetic alterations associated with MPD and MDS. It is also part of large-scale genomic and transcriptomic studies to understand the complexity of AML and its subtypes.

Research Applications

Study of JAK2 V617F mutation in myeloproliferative disordersInvestigation of JAK2 inhibition effectsGenomic and transcriptomic analysis of AMLUnderstanding molecular mechanisms of leukemogenesis

Key Characteristics

JAK2 V617F mutationDerived from MPD/MDS patientUsed in drug sensitivity studies

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1619
Species	Homo sapiens (Human)
Tissue Source	Peripheral blood[UBERON:UBERON_0000178]

Donor Information

Age	65
Age Category	Adult
Sex	Male

Disease Information

Disease	Acute myeloid leukemia
Lineage	Myeloid
Subtype	Acute Myeloid Leukemia
OncoTree Code	AML

DepMap Information

Source Type	DSMZ
Source ID	ACH-000113_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
Gene fusion	AFDN	KMT2A-AFDN, MLL-MLLT4, MLL-AF6	-	-	PubMed=15951289, PubMed=15921626

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

10,12

D13S317

11,12

D16S539

12,13

D18S51

D19S433

13,14

D21S11

D2S1338

23,25

D3S1358

D5S818

D7S820

D8S1179

12,15

FGA

19,24

Penta D

Penta E

12,14

TH01

6,9.3

TPOX

vWA

14,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOI PubMed PMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.

Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.

Leukemia 20:471-476(2006).

DOI PubMed

Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.

Fioretos T.

Leukemia 19:1042-1050(2005).

DOI PubMed

Expression of a retinoic acid receptor gene in myeloid leukemia cells.

Wang C., Curtis J.E., Minden M.D., McCulloch E.A.

Leukemia 3:264-269(1989).

PubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI